The FTC’s five Commissioners issue letters on behalf of the Commission in response to requests from Congress, industry, or the public to share information on a range of important topics and express the views of the Commission. Individual Commissioners may also issue letters to express their own individual views.
Displaying 21 - 40 of 53
Commissioner Brill’s letter to the ERISA Advisory Council Regarding PBM Compensation and Fee Disclosure
Date
By
Julie Brill, Former Commissioner
Commission Letter From Jessica L. Rich, Director of the Bureau of Consumer Protection, Filed With the Bankruptcy Court for the Southern District of New York -- in In re ConnectEDU, Inc., No. 14-11238 (Bankr. S.D.N.Y.)
Date
By
Jessica L. Rich, Former Director, Bureau of Consumer Protection
File
Text of the Commission Letter
(333.61 KB)
Letter from Chairwoman Edith Ramirez to Viviane Reding, European Commission Vice-President in Charge of Justice, Fundamental Rights and Citizenship
Date
By
Edith Ramirez, Former Chairwoman
RELATED LETTER: Privacy Enforcement and Safe Harbor: Comments of the FTC Staff to European Commission Review of the U.S.-EU Safe Harbor Framework (November 12, 2013)
Office Depot, Inc./OfficeMax, Inc.
Date
Matter Number
131 0104
Letter to World Wide Web Consortium Tracking Protection Working Group
Date
By
J. Thomas Rosch, Former Commissioner
Commission Letter Approving Aristotle, Inc.’s Safe Harbor Program Application Under the Children's Online Privacy Protection Rule
Date
Matter Number
P114509
File
Aristotle Safe Harbor approval letter
(85.04 KB)
Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs
Date
By
Mary K. Engle, Associate Director
Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs
Date
By
Mary K. Engle, Associate Director
Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs
Date
By
Mary K. Engle, Associate Director
Mary K. Engle
Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs
Date
By
Mary K. Engle, Associate Director
Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs
Date
By
Mary K. Engle, Associate Director
Displaying 21 - 40 of 53